
    
      Rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaric coenzyme
      A (HMG-CoA), an enzyme regulating the rate of cholesterol synthesis. Its main area of action
      is the liver.

        -  In cases of primary hypercholesterolaemia (type IIa, including familial
           hypercholesterolemia heterozygote) or mixed dyslipidaemia (type IIb) as a supplement to
           diet when dietary and other non-medication responses are inadequate.

        -  In cases of homozygous familial hypercholesterolemia (HoFH), as a supplement to the diet
           and other lipid-lowering treatments.

        -  In cases of slowing the progression of atherosclerosis. It is indicated as a
           supplemental treatment of the diet in lowering the total cholesterol (Total C) and LDL-C
           values.

        -  In patients with hypertriglyceridaemia (excess triglycerides in the blood). Dosage and
           route of administration

        -  In hyperlipidemia, mixed dyslipidaemia, hypertriglyceridaemia, and slowing the
           progression of atherosclerosis, the recommended starting dose is 10 mg once a day.

        -  In homozygous familial hypercholesterolemia, the recommended starting dose is 20 mg once
           a day.

        -  In Asian patients, the recommended starting dose is 5mg once a day.

        -  In patients receiving ciclosporin, the dose of rosuvastatin should be set at 5 mg, while
           those taking the combination of Lopinavir
    
  